To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

NCT07303465 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

KRAS G12D Mutations
Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG: RNK08954

Sponsor

Ranok Therapeutics (Hangzhou) Co., Ltd.